Acorda Therapeutics
Acorda Therapeutics
  • Home
  • About
    Acorda
    • About Acorda
    • Company
      Leadership
      • Company Leadership
      • Management
        Team
      • Board of
        Directors
      • Partnering
        With Acorda
    • Grant
      Program
    • Scientific
      Award
    • Compliance
      • Compliance
      • Acorda
        Compliance
      • Biotie EFPIA
        Disclosures
    • Message from
      BIO
    • Diversity and
      Inclusion
    • Contact Us
  • For
    Patients
    • For Patients
    • Focus On
      Therapies
    • In the
      Community
    • Resources
    • Policy on Access to
      Unapproved Medicines
  • Products &
    Research
    • Products & Research
    • Pipeline
    • ARCUS ®
      Technology
    • Products
      • Products
      • AMPYRA®
        (dalfampridine)
      • QUTENZA® (capsaicin)
        8% patch
    • Clinical
      Trials
    • Research &
      Development
      • Research & Development
      • CVT-301
      • SYN120
      • BTT1023
        (timolumab)
      • CVT-427
      • rHIgM22
  • Investors
    • Investors
    • Corporate
      Governance
    • Stock
      Information
    • Investor
      Events
    • Investor
      News
    • Financial
      Information
      • Financial Information
      • Quarterly
        Reports
      • Annual
        Reports
      • SEC Filings
      • Analysts
    • Investor
      Resources
      • Investor Resources
      • Investor Kit
      • E-mail
        Alerts
      • FAQs
      • IR Contact
  • News &
    Events
    • News & Events
    • In the News
    • Awards
    • Press Releases
    • Social Media
  • Careers
    • Careers
    • Working at
      Acorda
    • Our
      Employees
    • Benefits
    • Job Openings
    • Internship
      Program
    • Application
  • Privacy Policy
  • Terms of Use
  • Site Map
  • Contact Us
About Acorda

About Acorda

The one thing you should know about Acorda Therapeutics is that everything we do is aimed at improving the lives of millions of people with nervous system disorders...

LEARN MORE ›
For Patients

For Patients

We founded Acorda to bring life-changing therapies to people living with a wide range of nervous system disorders...

LEARN MORE ›
News & Events

News & Events

Acorda maintains open dialogue with patients, caregivers, healthcare professionals
and investors...

LEARN MORE ›
Investors

Investors

Acorda Therapeutics, Inc. is a biotechnology company whose mission is to develop and
market therapies...

LEARN MORE ›
Careers

Careers

We look for talented, Motivated people who want to make a difference in people's lives...

LEARN MORE ›
Fred<small>Ampyra (dalfampridine) Patient Since 2010</small>

FredAmpyra (dalfampridine) Patient Since 2010

LEARN ABOUT AMPYRA® ›
Leah<small>Ampyra (dalfampridine) Patient Since 2010</small>

LeahAmpyra (dalfampridine) Patient Since 2010

LEARN ABOUT AMPYRA® ›
Susan<small>Ampyra (dalfampridine) Patient Since 2010</small>

SusanAmpyra (dalfampridine) Patient Since 2010

LEARN ABOUT AMPYRA® ›
Products & Research

Products & Research

We have a deep understanding and experience in nervous systems research, product development and commercialization...

LEARN MORE ›

Wednesday, May 2, 2018 Acorda Provides Financial and Pipeline Update for First Quarter 2018

MORE NEWS

Fortune's "Best Workplaces"

2nd Year Among Fortune's "Best Workplaces for Women"

Acorda Scientific Excellence Award

Among "Best Places to Work" Annually Since 2011

The corporate culture comes…

primarily from Ron (Ron Cohen, CEO). He defined in the beginning what the simple core elements of the culture would be, but as we grow larger, it’s left up to the leaders of individual groups to continue that with the new faces coming in…

Andrew Blight See the Video
See the Video
  • About Acorda
    • Company Leadership
      • Management Team
      • Board of Directors
      • Partnering With Acorda
    • Grant Program
    • Scientific Award
    • Compliance
      • Acorda Compliance
      • Biotie EFPIA Disclosures
    • Message from BIO
    • Diversity and Inclusion
    • Contact Us
  • For Patients
    • Focus On Therapies
    • In the Community
    • Resources
    • Policy on Access to Unapproved Medicines
  • Products & Research
    • Pipeline
    • ARCUS® Technology
    • Products
      • AMPYRA® (dalfampridine)
      • QUTENZA® (capsaicin) 8% patch
    • Clinical Trials
    • Research & Development
      • CVT-301
      • SYN120
      • BTT1023 (timolumab)
      • CVT-427
      • rHIgM22
  • Investors
    • Corporate Governance
    • Stock Information
    • Investor Events
    • Investor News
    • Financial Information
      • Quarterly Reports
      • Annual Reports
      • SEC Filings
      • Analysts
    • Investor Resources
      • Investor Kit
      • E-mail Alerts
      • FAQs
      • IR Contact
  • News & Events
    • In the News
    • Awards
    • Press Releases
    • Social Media
  • Careers
    • Working at Acorda
    • Our Employees
    • Benefits
    • Job Openings
    • Internship Program
    • Application
Acorda Therapeutics
  • Privacy Policy
  • Terms of Use
  • Site Map
  • Contact Us

Alert

...

You are now leaving the Acorda.com site. By clicking "Ok", you will be leaving this website (sponsored by Acorda Therapeutics, Inc.) to enter an external and entirely independent website.

Acorda.com provides this link as a service and assumes no responsibility for any information presented on external websites.

OK
Cancel

If you’ve been impacted by Hurricane Harvey, Irma, or Maria, and have concerns about your Ampyra (dalfampridine) prescription, please contact your Specialty Pharmacy or Ampyra Patient Support Services at (888) 881-1918

Continue to www.acorda.com

Acorda has acquired Biotie Therapies. We invite you to explore www.acorda.com to learn more about our company, including our continued development of BIotie clinical programs for tozadenant, SYN120 and BTT1023. Information regarding transfers of value made to healthcare professionals and healthcare organizations in connection with Biotie’s clinical development programs is also available.

The website uses cookies, which are text files placed on your computer. Some of these are essential to the site’s operation while others analyse how visitors use the site. These cookies are set by default but you can disable them or view more information about how they are used here. By clicking on continue you consent to our use of cookies.

Click here to access Biotie’s EFPIA Disclosure Page
Continue to www.acorda.com
...

Acorda Named One of 100 Best Workplaces for Women 2015

Click for more information